Literature DB >> 14991747

Caspase-8 levels affect necessity for mitochondrial amplification in death ligand-induced glioma cell apoptosis.

Melissa J Knight1, Christopher D Riffkin, Paul G Ekert, David M Ashley, Christine J Hawkins.   

Abstract

Fifty percent of high-grade glioma patients die within a year of diagnosis and less than two percent survive five years postdiagnosis. Elucidating apoptosis signaling pathways may assist in designing better adjuvant therapies. Preliminary characterizations suggested that glioma cells may either employ mitochondrial-independent or -dependent death receptor-induced apoptotic pathways, characteristic of cells termed type I and type II, respectively. In the present study, we generated panels of clonal transfectants overexpressing various levels of Bcl-2, in two parental glioma cell lines. These cells were used to explore molecular factors determining the necessity for mitochondrial amplification of death receptor signaling. Moderate Bcl-2 expression was sufficient to render one glioma cell line (D270) resistant to apoptosis induced by Fas ligand or TRAIL, consistent with these cells being type II. However, expression of even very high levels of Bcl-2 in a second line (D645) did not affect death ligand sensitivity, indicative of a type I phenotype. D270 cells expressed much less caspase-8 protein than D645 cells. Enforced overexpression of caspase-8 (or cytoplasmic Diablo/Smac) in D270 cells overcame Bcl-2 inhibition of death ligand-induced apoptosis, converting them from type II to type I. This indicates that caspase-8 levels can influence the requirement for mitochondrial involvement in death receptor apoptotic signaling in glioma cells. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991747     DOI: 10.1002/mc.20011

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  TRAIL treatment provokes mutations in surviving cells.

Authors:  M M Lovric; C J Hawkins
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

2.  In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.

Authors:  D M Ashley; C D Riffkin; M M Lovric; T Mikeska; A Dobrovic; J A Maxwell; H S Friedman; K J Drummond; A H Kaye; H K Gan; T G Johns; C J Hawkins
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

3.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Yongming Li; Jiqin Lian; Theodore S Lawrence; Liang Xu
Journal:  BMC Cancer       Date:  2009-11-06       Impact factor: 4.430

4.  Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis.

Authors:  David Y L Chan; George G Chen; Wai S Poon; Pi C Liu
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

5.  Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.

Authors:  Mark A Miles; Christine J Hawkins
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.